Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Antimicrobials Post Transplant

A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation

Bone Marrow Transplantation volume 34, pages 447–453 (2004)Cite this article

Summary:

Patients with severe graft-versus-host disease (GVHD) requiring intensive immunosuppression are at high risk of invasive mould infections (IMI). Prophylaxis with an active, oral antifungal agents with reliable absorption in this context is desirable. A total of 44 patients at high risk of post-engraftment IMI received itraconazole solution 2.5 mg/kg b.d. as prophylaxis. Two of the first nine patients, in whom bioavailability was compromised due to significant vomiting and/or diarrhoea, died of probable or proven invasive aspergillus. None of the subsequent 35 patients, some of whom had severe gut GVHD and who received liposomal amphotericin B prophylaxis until itraconazole was reliably tolerated and absorbed, developed IMI. The overall incidence of IMI was substantially lower than in historical controls. Itraconazole was generally well tolerated, with five patients (11%) ceasing the drug due to intolerance or disturbed liver function. Targeted prophylaxis with oral or parenteral antifungal agents in high-risk allograft recipients appears to be effective in reducing the incidence of IMI.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Wingard JR . Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5: 55–68.

    Article  CAS  PubMed  Google Scholar 

  2. Wald A, Leisenring W, van Burik JA, Bowden RA . Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466.

    Article  CAS  PubMed  Google Scholar 

  3. Yuen KY, Woo PCY, Ip MSM et al. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997; 25: 37–42.

    Article  CAS  PubMed  Google Scholar 

  4. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801–808.

    Article  CAS  PubMed  Google Scholar 

  5. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.

    Article  CAS  PubMed  Google Scholar 

  6. O'Donnell MR, Schmidt GM, Tegtmeier BR et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827–834.

    Article  CAS  PubMed  Google Scholar 

  7. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic haematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833.

    Article  CAS  PubMed  Google Scholar 

  8. Lionakis MS, Kontoyiannis DP . Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828–1838.

    Article  CAS  PubMed  Google Scholar 

  9. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H . Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999–1004.

    Article  CAS  PubMed  Google Scholar 

  10. Ribaud P, Chastang C, Latge JP et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–330.

    Article  CAS  PubMed  Google Scholar 

  11. Grigg A . Prophylaxis and treatment of patients with aspergillosis: an overview, including the Royal Melbourne Hospital experience. J Antimicrob Chemother 2002; 49: 75–80.

    Article  CAS  PubMed  Google Scholar 

  12. Thursky K, Byrnes G, Grigg A et al. A predictive model for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115–121.

    Article  CAS  PubMed  Google Scholar 

  13. Rousey SR, Russler S, Gottlieb M, Ash RC . Low-dose amphotericin B prophylaxis against invasive aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91: 484–491.

    Article  CAS  PubMed  Google Scholar 

  14. Schwartz S, Behre G, Heinemann V et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654–3661.

    CAS  PubMed  Google Scholar 

  15. Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577–582.

    CAS  PubMed  Google Scholar 

  16. Denning DW, Hostetler JS, Kauffman CA et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–144.

    Article  CAS  PubMed  Google Scholar 

  17. Tricot G, Joosten E, Boogaerts MA et al. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987; 9: S94–S99.

    Article  PubMed  Google Scholar 

  18. Todeschini G, Murari C, Bonesi R et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with Hematological malignancies. Eur J Clin Microbiol Infect Dis 1993; 12: 614–618.

    Article  CAS  PubMed  Google Scholar 

  19. Vreugdenhil G, Van Dijke BJ, Donnelly JP et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993; 11: 353–358.

    Article  CAS  PubMed  Google Scholar 

  20. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901–911.

    Article  CAS  PubMed  Google Scholar 

  21. Bradford CR, Prentice AG, Warnock DW, Copplestone JA . Comparison of multiple dose pharmacokinetics of two formations of itraconazole during remission induction for acute myeloblastic leukemia. J Antimicrob Chemother 1991; 28: 555–560.

    Article  CAS  PubMed  Google Scholar 

  22. Prentice AG, Warnock DW . Itraconazole more bioavailable in solution. Blood 1996; 88: 3662.

    CAS  PubMed  Google Scholar 

  23. Yu VL, Muder RR, Poorsattar A . Significance of isolation of aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Am J Med 1986; 81: 249–254.

    Article  CAS  PubMed  Google Scholar 

  24. Van Cutsem J, Fan Gerven F, Janssen PAJ . Rev Infect Dis 1987; 9: 515.

  25. Back DJ, Tjia JF . Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624–626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.

    Article  CAS  PubMed  Google Scholar 

  27. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomised, double-blind study. J Infect Dis 1995; 171: 1545–1552.

    Article  CAS  PubMed  Google Scholar 

  28. Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768–2776.

    Article  CAS  PubMed  Google Scholar 

  29. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833.

    Article  CAS  PubMed  Google Scholar 

  30. Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615–4626.

    Article  CAS  PubMed  Google Scholar 

  31. Winston DJ, Maziars RT, Pranatharthi H et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic haematopoietic stem-cell transplant recipients. Ann Intern Med 2003; 138: 705–713.

    Article  CAS  PubMed  Google Scholar 

  32. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2004; 103: 1527–1533.

    Article  CAS  PubMed  Google Scholar 

  33. Boogaerts MA, Maertens J, van Der Geest R et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14 day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrobial Agents Chemother 2001; 45: 981–985.

    Article  CAS  Google Scholar 

  34. Winston DJ, Emmanouilides C, Bartoni K et al. Elimination of aspergillus as a significant pathogen in an allogeneic hematopoietic stem cell transplant program after introduction of routine long-term itraconazole prophylaxis. Blood 2003; 102: 197a (Abstr. # 685).

    Google Scholar 

  35. Marr KA, Leisening W, Crippa F, Slattery JT et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557–1559.

    Article  CAS  PubMed  Google Scholar 

  36. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147.

    Article  CAS  PubMed  Google Scholar 

  37. Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating glactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610.

    Article  CAS  PubMed  Google Scholar 

  38. Hebart H, Loffler J, Meisner C et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181: 1713–1719.

    Article  CAS  PubMed  Google Scholar 

  39. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32: 103–108.

    Article  PubMed  Google Scholar 

  40. Glasmacher A, Hahn C, Molitor E et al. Definition of an itraconazole target concentration for antifungal prophylaxis. Abstracts of 40th conference on antimicrobial agents and chemotherapy, September 2000. Am Soc Microbiol 2000; 363.

  41. Lamy T, Bernard M, Courtois A et al. Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. Leuk Lymph 1998; 30: 163–174.

    Article  CAS  Google Scholar 

  42. Ahmad SR, Singer SJ, Leissa BG . Congestive heart failure associated with itraconazole. Lancet 2001; 357: 1766–1767.

    Article  CAS  PubMed  Google Scholar 

  43. Warris A, Weemaes CM, Veerweij PE . Multidrug resistance in aspergillus fumigatus. N Engl J Med 2002; 347: 2173–2174.

    Article  PubMed  Google Scholar 

  44. Westerman DA, Speed BR, Prince HM . Fatal disseminated infection by scedosporium prolificans during induction therapy for acute leukemia: a case report and literature review. Pathology 1999; 31: 393–394.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Haematology and Medical Oncology, Bone Marrow Transplant Service, Royal Melbourne Hospital, Australia

    A P Grigg, M Brown, A W Roberts & J Szer

  2. Centre for Clinical Research Excellence in Infectious Disease, Royal Melbourne Hospital, Australia

    M A Slavin

Authors
  1. A P Grigg
    View author publications

    Search author on:PubMed Google Scholar

  2. M Brown
    View author publications

    Search author on:PubMed Google Scholar

  3. A W Roberts
    View author publications

    Search author on:PubMed Google Scholar

  4. J Szer
    View author publications

    Search author on:PubMed Google Scholar

  5. M A Slavin
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to A P Grigg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grigg, A., Brown, M., Roberts, A. et al. A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. Bone Marrow Transplant 34, 447–453 (2004). https://doi.org/10.1038/sj.bmt.1704614

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704614

Keywords

This article is cited by

Search

Advanced search

Quick links